Pharmaceutical Executive-09-01-2011

From Many, One

Bill Trombetta surveys the landscape of pharma financials over the past year, and shows which companies rode the wave to the top of the industry in delivering value to shareholders.

Diagnostics can bost the efficacy of drug treatments, but delivering the promise depends on a predictible pathway to reimbursement.

The time is right for industry to overcome its social media phobia once and for all.

Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health?

Pharm Exec talks to Dr. Mel Spigelman, President and CEO of the TB Alliance, about the organization's tuberculosis priorities.

Tata Consultancy Services has grown into one of the largest IT solutions providers in the world

Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.

Within an industry that traditionally moves at a slow pace, the rapidly changing playing field as required both Indian pharmaceutical companies, as well as MNCs, to adjust their strategies accordingly

PricewaterhouseCooper's "Global Construction 2020" report predictions

User-fee renewal legislation sets the stage for new policies affecting reimbursement, research, and regulatory oversight.

Especially when payers come to the table holding the best cards - leaving industry second-guessing its strategy.

Q&A with Satish, Reddy, MD, COO of Dr. Reddy's Labs

Observational studies present a compelling real-world corollary to the classic randomized clinical trial.

Despite the gloom, most forecasts show the US will stay atop the industry in profits for at least the next generation of products.

Keeping your finger on the pulse of consumers leads to better, more actionable insights-and better results.

Gujarati has become one of India's most industrialized states